Tag: bnt162b2

1. Heterologous AstraZeneca followed by Pfizer vaccination was noninferior to homologous, two-dose AstraZeneca vaccination with a geometric mean ratio of 9.2. 2. Heterologous Pfizer followed by AstraZeneca vaccination was not found to be non-inferior to homologous, two-dose Pfizer vaccination. Evidence Rating Level: 1 (Excellent) Study Rundown: Heterologous prime-boost vaccination schedules involve administering...
Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering the...
1. Levels of antibodies against the trimeric spike protein and receptor-binding domain were 36- and 77-fold higher in the BNT162b2 group compared to control. 2. There were no vaccine-related serious adverse events. Evidence Rating Level: 1 (Excellent)  Study Rundown: Current research on COVID-19 vaccination has revolved around a homologous dosing schedule (administering...
1. There was a vaccine efficacy of 97.2% against symptomatic COVID-19 infection in individuals at least 7 days after their second vaccine dose. 2. Substantial and consistent declines in COVID-19 incidence corresponded to greater vaccine coverage. Evidence Rating Level: 2 (Good) Study Rundown: Beyond clinical trials, there is growing evidence of the...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19 vaccines have been...
1. Vaccinated individuals reported fewer SARS-CoV-2 infections and a lesser proportion of cases were symptomatic compared to the unvaccinated cohort. 2. BNT162b2 mRNA vaccine showed an effectiveness of 70% 21 days after a single dose. Evidence Rating Level: 2 (Good)  Study Rundown: The BNT162b2 mRNA (Pfizer-BioNTech) and ChAdOx1 nCoV-19 adenoviral (Oxford-AstraZeneca) COVID-19...
1. The initial doses of the Pfizer and AstraZeneca vaccines were 91% and 88% efficacious in reducing COVID-19 hospitalizations one month after vaccination. 2. Combined vaccine efficacy of the Pfizer and AstraZeneca in preventing hospital admission due to COVID-19 among those aged 80 years and older was approximately 83%. Evidence Rating...
Section 1: Pfizer/BioNTech Vaccine First to Receive Emergency Use Authorization to Prevent COVID-19 On December 11, 2020, the U.S. Food and Drug Administration (FDA) approved for emergency use the first vaccine to prevent coronavirus disease 2019 (COVID-19).1 This vaccine includes BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA and encodes a prefusion stabilized,...